<DOC>
	<DOC>NCT02174679</DOC>
	<brief_summary>To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.</brief_summary>
	<brief_title>68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)</brief_title>
	<detailed_description>This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.</detailed_description>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<criteria>Older than 18 years the time of radiotracer administration Provides written informed consent Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline Able to remain still for duration of each imaging procedure (about 30 minutes) Less than 18 yearsold at the time of radiotracer administration Pregnant or nursing Inability to complete the needed investigational and standardofcare imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>